View Older Stories View More Recent Stories

May 7, 2024 04:16PM CytomX Therapeutics (CTMX) Enters Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA
May 7, 2024 04:15PM CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
May 1, 2024 08:00AM CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
Apr 8, 2024 08:00AM CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Apr 3, 2024 08:00AM CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Mar 21, 2024 08:01AM CytomX Therapeutics (CTMX) Appoints Dr. Zhen Su to its Board
Mar 21, 2024 08:00AM CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Mar 18, 2024 08:00AM CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Mar 11, 2024 04:10PM CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
Mar 4, 2024 08:00AM CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Feb 27, 2024 08:00AM CytomX Therapeutics to Present at Upcoming March Investor Conferences
Jan 24, 2024 08:01AM CytomX Therapeutics (CTMX) Announces FDA Clearance of IND Applications for CX-2051
Jan 24, 2024 08:00AM CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
Jan 12, 2024 08:00AM CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
Jan 4, 2024 08:00AM CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
Dec 21, 2023 08:00AM CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 7, 2023 04:15PM CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 1, 2023 08:00AM CytomX Therapeutics to Present at Upcoming November Investor Conferences
Oct 31, 2023 08:00AM CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
Oct 30, 2023 08:00AM CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting
Oct 18, 2023 04:30PM CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
Sep 5, 2023 04:05PM CytomX Therapeutics to Present at Upcoming September Investor Conferences
Aug 10, 2023 04:05PM CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
Aug 8, 2023 04:15PM CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 1, 2023 08:00AM CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
Jul 20, 2023 09:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Jul 17, 2023 08:03AM CytomX Therapeutics (CTMX) Appoints Yu-Waye Chu as Chief Medical Officer
Jul 17, 2023 08:00AM CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
Jun 30, 2023 08:01AM CytomX Therapeutics (CTMX) Announces $30 Million Private Placement from BVF Partners L.P.
Jun 30, 2023 08:00AM CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
Jun 1, 2023 04:05PM CytomX Therapeutics to Present at the Jefferies Healthcare Conference
May 9, 2023 04:15PM CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023 04:01PM CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
Apr 25, 2023 04:05PM CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Mar 27, 2023 04:15PM CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Mar 22, 2023 07:23PM CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
Feb 28, 2023 04:05PM CytomX Therapeutics to Present at Upcoming March Investor Conferences
Jan 26, 2023 07:07AM CytomX Therapeutics (CTMX) Announces Milestone Achievement in Probody T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Jan 26, 2023 07:00AM CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Jan 17, 2023 04:05PM CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
Jan 5, 2023 04:09PM CytomX Therapeutics (CTMX) Provides Business Update and Outlines 2023 Goals
Jan 5, 2023 04:06PM Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Jan 5, 2023 04:05PM CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Jan 5, 2023 04:05PM CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
Jan 5, 2023 04:05PM Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Dec 22, 2022 05:00PM CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
Dec 20, 2022 05:00PM CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 7, 2022 04:30PM CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
Nov 17, 2022 07:01AM Regeneron (REGN) and CytomX (CTMX) Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Nov 17, 2022 07:00AM CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
View More Recent Stories View Older Stories